Stent maker InspireMD's Q2 revenue beats estimates

InspireMD

05/08/2025 13:09

Overview

InspireMD Q2 revenue rises 2.3%, beating analyst expectations, per LSEG data

Net income for Q2 missed analyst expectations, per LSEG data

Co received FDA approval and launched CGuard Prime in U.S. market

Outlook

Company plans to launch CGuard Prime in Europe in Q3

InspireMD focuses on scaling operations post-U.S. launch

Company aims to establish CGuard as standard for carotid disease

Result Drivers

FDA APPROVAL - Received FDA approval for CGuard Prime carotid stent system, driving U.S. market launch

EXCHANGE RATES - Revenue positively impacted by exchange rates, offsetting decreased revenue from Russia

OPERATING EXPENSES - Increased due to U.S. sales force expansion and CGuard Prime launch preparation

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$1.78 mln
$1.52 mln (2 Analysts)
Q2 Net Income
Miss
-$13.15 mln
-$12.90 mln (2 Analysts)
Q2 Income From Operations
Beat
-$13.02 mln
-$13.10 mln (2 Analysts)
Q2 Basic EPS
-$0.26
Q2 Gross Profit
$313,000
Q2 Operating Expenses
$13.33 mln


Press Release: ID:nGNX4ZbSXW

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)